PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations
- PMID: 28495986
- DOI: 10.1161/CIRCRESAHA.117.311015
PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations
Comment on
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.
-
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Clinical Trial.
Similar articles
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
-
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Circulation. 2015. PMID: 26503748 Review.
-
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.Adv Ther. 2020 Apr;37(4):1496-1521. doi: 10.1007/s12325-020-01259-4. Epub 2020 Feb 27. Adv Ther. 2020. PMID: 32108309
-
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes.Clin Ther. 2022 Feb;44(2):331-348. doi: 10.1016/j.clinthera.2021.12.005. Epub 2022 Mar 1. Clin Ther. 2022. PMID: 35246337 Review.
-
Status of PCSK9 Monoclonal Antibodies in Australia.Heart Lung Circ. 2019 Oct;28(10):1571-1579. doi: 10.1016/j.hlc.2019.04.014. Epub 2019 May 8. Heart Lung Circ. 2019. PMID: 31104887 Review.
Cited by
-
Estimating the Risk of Cardiovascular Events in U.S. Veterans Using the SMART Risk Score.JACC Adv. 2024 Dec 12;4(1):101459. doi: 10.1016/j.jacadv.2024.101459. eCollection 2025 Jan. JACC Adv. 2024. PMID: 39759440 Free PMC article.
-
Physical Activity, Immune System, and the Microbiome in Cardiovascular Disease.Front Physiol. 2018 Jun 29;9:763. doi: 10.3389/fphys.2018.00763. eCollection 2018. Front Physiol. 2018. PMID: 30013482 Free PMC article.
-
Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis.Theranostics. 2020 Mar 4;10(9):3952-3966. doi: 10.7150/thno.39578. eCollection 2020. Theranostics. 2020. PMID: 32226531 Free PMC article.
-
The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application.Mediators Inflamm. 2022 Jun 17;2022:3101900. doi: 10.1155/2022/3101900. eCollection 2022. Mediators Inflamm. 2022. PMID: 35757107 Free PMC article. Review.
-
Multiomic integration analysis identifies atherogenic metabolites mediating between novel immune genes and cardiovascular risk.Genome Med. 2024 Oct 24;16(1):122. doi: 10.1186/s13073-024-01397-2. Genome Med. 2024. PMID: 39449064 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous